RxDoctor Payments Data

Abul Basher, MD

Cardiovascular Disease · Michigan City, INNPI 1891784500

Payments from drug & device makers

$4,456in general payments, 2019–2025

Across 267 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$862
  • Pfizer$731
  • Merck$477
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$256
  • AstraZeneca$252
  • E.r. Squibb & Sons, L.L.C.$246
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,34798%
  • Education$1092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,456 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$112,850
Medicare patients
1,093
Services billed
2,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$133,675
EntrestoSacubitril/Valsartan32$38,116
XareltoRivaroxaban18$24,489
Repatha SureclickEvolocumab23$14,869
Ezetimibe349$6,861
Nebivolol Hcl78$4,412
Ranolazine ErRanolazine44$3,629
Flecainide Acetate18$2,415
Metoprolol Succinate161$2,217
Atorvastatin Calcium131$1,133
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$874
Rosuvastatin Calcium88$870
Losartan Potassium112$722
ClopidogrelClopidogrel Bisulfate45$615
Amlodipine Besylate116$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$731$133,675105 claims
NovartisEntresto$862$38,11632 claims
Johnson & JohnsonXarelto$212$24,48918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →